U.S. markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.81%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • GBP/USD

    1.3921
    -0.0091 (-0.65%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.30%)
     
  • BTC-USD

    47,108.84
    +1,002.11 (+2.17%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

UNITY Biotechnology, Inc. Reports Second Quarter 2020 Financial Results and Clinical Program Updates

  • Oops!
    Something went wrong.
    Please try again later.
Unity Biotechnology, Inc.
·8 min read
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the second quarter ended June 30, 2020.

“We are pleased with the progress we are making on advancing programs that target senescent cells to alter the course of diseases of aging,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “The second half of 2020 is a very important period for UNITY, with our topline 12-week Phase 2 data readout from the UBX0101 program in osteoarthritis expected in the third quarter, as well as the commencement of our initial clinical program in ophthalmology later in the second half of the year.”

Clinical Program Updates

Osteoarthritis – UBX0101

In July 2020, UNITY announced that it expects to announce topline 12-week results from its Phase 2 study of UBX0101 in the third quarter of 2020. Consistent with prior guidance, 24-week results are also expected by the end of 2020. The company previously announced completion of enrollment of a Phase 2 study of UBX0101 in patients with moderate-to-severe osteoarthritis (OA) of the knee in February 2020. The study is randomized, double-blind, and placebo-controlled and will evaluate three doses (0.5 mg, 2.0 mg and 4.0 mg) of UBX0101 administered via a single intra-articular injection.

UNITY is also conducting a Phase 1b study of UBX0101 in patients with moderate-to-severe OA of the knee. Enrollment in this study was completed in March 2020. The study is randomized, double-blind, and placebo-controlled and will explore the safety, tolerability and initial efficacy of a single 8.0 mg dose or multiple doses (two 4.0 mg doses separated by one month) of UBX0101. Consistent with prior guidance, both 12- and 24-week results are expected in the second half of 2020.

Ophthalmology – UBX1325

In July 2020, UNITY announced that it has completed Investigational New Drug application (IND) -enabling studies with UBX1325, an investigational senolytic, small molecule inhibitor of the anti-apoptotic Bcl-2 family member, Bcl-xL. Assuming clinical sites are able to recruit and retain investigators and study staff and screen and enroll patients during the ongoing COVID-19 pandemic, UNITY expects to initiate a Phase 1 safety study for UBX1325 in the second half of 2020 and obtain initial results from the study in 2021. The overall clinical program is directed at multiple age-related diseases of the eye, such as diabetic macular edema, diabetic retinopathy and age-related macular degeneration.

Financial Outlook

UNITY believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the second half of 2021.

Second Quarter Financial Results

Cash, cash equivalents and marketable securities totaled $111.8 million as of June 30, 2020 compared with $125.0 million as of December 31, 2019.

Operating loss for the three months ended June 30, 2020 was $23.3 million compared to $24.5 million for the three months ended June 30, 2019. Cash used in operations during the six months ended June 30, 2020 was $44.4 million compared to $39.9 million for the six months ended June 30, 2019.

Research and development expenses decreased by $2.3 million, to $16.1 million for the three months ended June 30, 2020 from $18.5 million for the three months ended June 30, 2019. The decrease was primarily due to a decrease of $5.3 million in pre-clinical and manufacturing expenses partially offset by a $1.8 million increase in clinical study related costs, driven by progression of UBX0101 to clinical stage, and increases of $1.2 million in personnel-related costs, of which $1.0 million was related to non-cash stock compensation expense.

General and administrative expenses increased by $1.4 million, to $6.3 million for the three months ended June 30, 2020 from $5.0 million for the three months ended June 30, 2019. The increase was primarily due to increases of $1.2 million in non-cash stock compensation expense, and $0.2 million in facilities-related fees.

About UNITY

UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby provide transformative benefit in age-related diseases, such as osteoarthritis, eye diseases, neurological diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.

Forward-Looking Statements

This press release contains forward-looking statements including statements related to the potential for UNITY to develop therapeutics to extend healthspan, the timing of certain regulatory filings, expectations regarding the results of its clinical studies and timing of announcements of such results and the sufficiency of its cash, cash equivalents and marketable securities. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the Securities and Exchange Commission on July 31, 2020, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

Unity Biotechnology, Inc.
Condensed Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)

Three Months Ended

Six Months Ended

June 30,

June 30,

2020

2019

2020

2019

Operating expenses:

Research and development

$

16.123

$

18.468

$

35.388

$

34.973

General and administrative

6.32

4.97

12.273

9.447

Change in fair value of contingent consideration

906

1.032

685

(213

)

Impairment of long-lived assets

2.159

Total operating expenses

23.349

24.47

50.505

44.207

Loss from operations

(23,349

)

(24,470

)

(50,505

)

(44,207

)

Interest income

340

900

867

1.906

Other income (expense), net

4.342

(103

)

2.933

(139

)

Net loss

(18,667

)

(23,673

)

(46,705

)

(42,440

)

Other comprehensive loss

Unrealized gain (loss) on marketable debt securities, net of tax

(141

)

94

142

208

Comprehensive loss

$

(18,808

)

$

(23,579

)

$

(46,563

)

$

(42,232

)

Net loss per share, basic and diluted

$

(0.38

)

$

(0.56

)

$

(0.96

)

$

(1.00

)

Weighted-average number of shares used in computing net loss per share, basic and diluted

49,659,153

42,442,886

48,606,768

42,311,040

Unity Biotechnology, Inc.
Condensed Balance Sheets
(In thousands)

June 30,

December 31,

2020

2019

(Unaudited)

Assets

Current Assets:

Cash and cash equivalents

$

39.592

$

37.473

Short-term marketable securities

72.176

84.508

Strategic investment

7.768

5.507

Prepaid expenses and other current assets

4.001

1.999

Total current assets

123.537

129.487

Property and equipment, net

14.226

16.636

Operating lease right of use asset

24.891

Long-term marketable securities

3.025

Restricted cash

1.446

1.446

Other long-term assets

598

627

Total assets

$

164.698

$

151.221

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable

$

3.952

$

5.185

Accrued compensation

3.651

5.905

Accrued and other current liabilities

6.25

4.995

Contingent consideration liability

1.816

1.131

Total current liabilities

15.669

17.216

Operating lease liability, net of current portion

36.77

Deferred rent, net of current portion

13.298

Total liabilities

52.439

30.514

Commitments and contingencies

Stockholders' equity:

Common stock

5

5

Additional paid-in capital

404.754

366.695

Related party promissory notes for purchase of common stock

(210

)

(210

)

Employee promissory notes for purchase of common stock

(362

)

(418

)

Accumulated other comprehensive income

232

90

Accumulated deficit

(292,160

)

(245,455

)

Total stockholders' equity

112.259

120.707

Total liabilities and stockholders' equity

$

164.698

$

151.221

Investors
Endurance Advisors
Peter Rahmer
prahmer@enduranceadvisors.com

Media
Canale Communications
Jason Spark
jason@canalecomm.com